News for Kadimastem Ltd (KMSTF)

PR NewswireZURICH, March 10, 2025 ZURICH, March 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical co

PR NewswireZURICH and NESS ZIONA, Israel, Feb. 25, 2025 Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Wit

PR NewswireZURICH and NESS ZIONA, Israel, Feb. 10, 2025 Revolutionizing Diabetes Treatment: Introduction of cutting-edge, multi-targeted innovation to tran

PR NewswireZURICH and NESS ZIONA, Israel, Jan. 16, 2025 Kadimastem Approaches Final Steps for Securing Merger CompletionZURICH and NESS ZIONA, Israel, Jan.

PR NewswireZURICH and NESS ZIONA, Israel, Dec. 30, 2024 The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates

NLS Pharmaceutics and Kadimastem eye January merger

ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage bioph

NLS Pharmaceutics reveals promising preclinical data

NLS Pharmaceutics to merge with Kadimastem in stock deal

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

Top Penny Pot Stocks To Watch This Week

/PRNewswire/ -- Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing treatments for ALS and diabetes, has been granted its third...